In a study published in Cell, a research team led by Zhu Shujia from the Center for Excellence in Brain Science and ...

In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...

The patent will not expire until at least 2034 and is part of Vistagen’s global patent portfolio on manufacturing methods and therapeutic uses for AV-101 to treat various disorders involving the NMDA ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced ...

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

Tests for paraneoplastic and voltage-gated potassium channel antibodies were negative, but antibodies to N-methyl-D-aspartate receptors (NMDARs) were identified in serum and CSF (Figure 2).

Patients with anti-NMDAR encephalitis may continue to have memory, language, and emotional issues up to 36 months following a diagnosis.

Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...

Revolutionizing Depression Treatment Spravato is a nasal spray that regulates mood by targeting the NMDA receptor in the brain. The action mechanism allows quicker relief from depressive symptoms ...